Newsletter April 2017

Awareness: The PCCN-Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: Join us on Father’s day morning for our annual “Do it for dads” Walk Run! Jan. Awareness Night: Dr. Raj Satkunasivam: The future of PSA-based prostate cancer screening: screening smarter and individualized risk assessment We’d like to welcome a new sponsor – JANSSEN PHARMACEUTICALS PCCN-Toronto Volunteers Participate in PCC’s “SHOP FOR A CAUSE” with Tommy Bahama Stores A new sponsor for our 2017 newsletter – KELLER WILLIAMS Neighbourhood Realty March Awareness Night: Dr. Joseph LaBossiere: Andrology: focuses on diseases & conditions specific to men! Ask the …

Newsletter April 2017 Read More »

Prostate Cancer Study Details Value of Treatments

A new study offers important information to men who are facing difficult decisions about how to treat prostate cancer in its early stages, or whether to treat it at all. Researchers followed patients for 10 years and found no difference in death rates between men who were picked at random to have surgery or radiation, or to rely on “active monitoring” of the cancer, with treatment only if it progressed. Read the article here.

New PET scan can detect prostate cancer earlier than MRIs and CT scans

Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after initial treatment and spread to other parts of the body. Prostate PET/CT scans can detect cancer earlier than either CT scans alone or MRI scans. Read the article here.

Biolyse Pharma stymied in effort to make cheaper version of pricey prostate cancer drug

A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price. Right now Xtandi costs U.S. patients as much as $129,000 US a year, or about $90 per pill. St. Catharines, Ont.-based Biolyse Pharma says it can make the drug for $3 a pill, or $4,400 per year, but has so far been unable to get U.S. health authorities to override the existing patent. Read the article here.

Prostate Cancer Treatment Breakthrough

Scientists with Deakin’s School of Medicine have found that, when coupled with the milk protein lactoferrin, the chemotherapy drug Doxorubicin (Dox) can be delivered directly into the nucleus of prostate cancer cells and will kill them cells as well as drug resistant cancer stem cells, without any side-effects. Read the article here.

Scroll to Top